| Lauren Adrienne Morin, MS, CCC-SLP | |
|
895 Portland Rd, Saco, ME 04072-9673 | |
| (207) 439-5104 | |
| Not Available |
| Full Name | Lauren Adrienne Morin |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 895 Portland Rd, Saco, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326645524 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SP3130 (Maine) | Primary |
| Provider Name | Saco Bay Orthopaedic And Sports Physical Therapy Inc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1346254315 PECOS PAC ID: 9537069265 Enrollment ID: O20040109000951 |
News Archive
Hwyda Arafat, M.D., Ph.D., Associate Professor of Surgery at Thomas Jefferson University and co-director of the Jefferson Pancreatic, Biliary and Related Cancers Center, and Mon-Li Chu, Ph.D., Professor and Vice Chair of the Department of Dermatology and Cutaneous Biology, were awarded $200,000 from the University City Science Center's QED Proof of Concept Program for their breakthrough work on a diagnostic test for pancreatic cancer.
Details of computer models that can predict the chances of a patient responding to their HIV drugs with 80% accuracy are published today in the journal AIDS. The models were developed by the HIV Resistance Response Database Initiative (RDI) using almost half a million pieces of data from approximately 6,000 clinical cases from hundreds of clinics around the world. The models are now available online as part of an experimental treatment support tool, HIV-TRePS.
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.
The increased demand for primary care services expected to result from the Affordable Care Act (ACA) may be felt strongly in rural areas. While studies have found that the quality of care delivered to rural patients is as good or better than that available in urban areas, the belief persists that top-quality primary care is only available in big cities.
› Verified 7 days ago
| Provider Name | Select Physical Therapy Holdings Inc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1427564590 PECOS PAC ID: 9537076401 Enrollment ID: O20180306000729 |
News Archive
Hwyda Arafat, M.D., Ph.D., Associate Professor of Surgery at Thomas Jefferson University and co-director of the Jefferson Pancreatic, Biliary and Related Cancers Center, and Mon-Li Chu, Ph.D., Professor and Vice Chair of the Department of Dermatology and Cutaneous Biology, were awarded $200,000 from the University City Science Center's QED Proof of Concept Program for their breakthrough work on a diagnostic test for pancreatic cancer.
Details of computer models that can predict the chances of a patient responding to their HIV drugs with 80% accuracy are published today in the journal AIDS. The models were developed by the HIV Resistance Response Database Initiative (RDI) using almost half a million pieces of data from approximately 6,000 clinical cases from hundreds of clinics around the world. The models are now available online as part of an experimental treatment support tool, HIV-TRePS.
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.
The increased demand for primary care services expected to result from the Affordable Care Act (ACA) may be felt strongly in rural areas. While studies have found that the quality of care delivered to rural patients is as good or better than that available in urban areas, the belief persists that top-quality primary care is only available in big cities.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lauren Adrienne Morin, MS, CCC-SLP 435 Bath Rd, Brunswick, ME 04011-2636 Ph: (207) 316-8822 | Lauren Adrienne Morin, MS, CCC-SLP 895 Portland Rd, Saco, ME 04072-9673 Ph: (207) 439-5104 |
News Archive
Hwyda Arafat, M.D., Ph.D., Associate Professor of Surgery at Thomas Jefferson University and co-director of the Jefferson Pancreatic, Biliary and Related Cancers Center, and Mon-Li Chu, Ph.D., Professor and Vice Chair of the Department of Dermatology and Cutaneous Biology, were awarded $200,000 from the University City Science Center's QED Proof of Concept Program for their breakthrough work on a diagnostic test for pancreatic cancer.
Details of computer models that can predict the chances of a patient responding to their HIV drugs with 80% accuracy are published today in the journal AIDS. The models were developed by the HIV Resistance Response Database Initiative (RDI) using almost half a million pieces of data from approximately 6,000 clinical cases from hundreds of clinics around the world. The models are now available online as part of an experimental treatment support tool, HIV-TRePS.
Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.
The increased demand for primary care services expected to result from the Affordable Care Act (ACA) may be felt strongly in rural areas. While studies have found that the quality of care delivered to rural patients is as good or better than that available in urban areas, the belief persists that top-quality primary care is only available in big cities.
› Verified 7 days ago
Heather Lynn Guevara, M.S., CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Beach St, Saco, ME 04072 Phone: 207-284-4505 | |
Kathryn Bear, M.S, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 5 Willey Rd, Saco, ME 04072 Phone: 207-494-9630 | |
Mary E Schiavoni, MS CCC Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 77 Burnham Rd, Saco, ME 04072 Phone: 207-284-9978 Fax: 207-799-2289 | |
Ms. Katherine Suzanne Alexander, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Beach St, Saco, ME 04072 Phone: 207-284-4505 | |
Saco Bay Orthopaedic And Sports Physical Therapy, Inc. Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 895 Portland Rd Rm 1, Saco, ME 04072 Phone: 207-439-5104 | |
Meredith A Carbone, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 90 Beach St, Saco, ME 04072 Phone: 207-284-4505 Fax: 207-284-5951 | |
Ashley Houp, MA CF-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 895 Portland Rd, Saco, ME 04072 Phone: 207-439-5104 |